Montelukast (Figure 1) was shown to suppress EMT and angiogenesis in triple-negative breast cancer (TNBC) through inhibition of the SIRT1/AKT signaling axis, reducing SIRT1 and vimentin expression while upregulating E-cadherin. This evidence concerns the gene SIRT1 and triple-negative breast carcinoma.